Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bezacitinib
- Development stage
- Phase 3
- Lead developer
- Hangzhou Bangshun Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Bezacitinib (OB756) is an orally bioavailable small molecule Janus kinase (JAK) inhibitor developed by Hangzhou Bangshun Pharmaceutical. It is currently in Phase 1 clinical development, specifically being evaluated for the treatment of type 1 diabetes mellitus. The drug is designed to modulate immune signaling pathways that contribute to the autoimmune destruction of pancreatic beta cells. Clinical trials in healthy participants have been initiated to characterize its safety, tolerability, pharmacokinetics, and pharmacodynamics, including relative bioavailability when administered as a tablet formulation.
- Brand names
- Bangruishun邦瑞顺
- Other names
- bezacitinib
02
Targets
Beyond the preview
Go deeper on bezacitinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bezacitinib.